News

14 June 2017 - Just Published: article on NLX-112 agonist properties in vitro

A new publications characterizes the distinctive in vitro agonist properties of NLX-112, a potential drug therapy for L-DOPA-induced dyskinesia (LID) in Parkinson's disease. NLX-112 was tested in a variety of in vitro assays of serotonin 5-HT1A receptor activation and consistently exhibited very high agonist efficacy. NLX-112 also exhibited preferential activation of a specific G-protein subtype (Go), unlike other compounds such as NLX-101, which is being developed by Neurolixis for Rett syndrome. Overall, the study provides further pharmacological support for the superior profile of NLX-112 compared to previous serotonergic agonists.

Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist

Newman-Tancredi A, Martel J-C, Cosi C, Heusler P, Lestienne F, Varney MA, Cussac D.
Journal of Pharmacy and Pharmacology, 2017 June 14. DOI: 10.1111/jphp.12762

 

20 December 2016 - Neurolixis CSO to present at Encéphale Congress in Paris

Adrian Newman-Tancredi, PhD, DSc, will present at the forthcoming Encéphale Congress to be held January 18-20, 2017 in Paris, France. Dr. Newman-Tancredi has been invited in his capacity as Chief Scientific Officer of Neurolixis to give a lecture on emerging drug discovery concepts for the development of novel antidepressants.

Dr. Newman-Tancredi's presentation will be part of the plenary session entitled "Psychopharmacology in the third millennium" on Wednesday 18 January 2017 and will focus on prospects for improved treatment of depressive disorders using highly selective 'biased agonists' targeting cortical serotonin 5-HT1A receptors.  

For full details of the Encéphale Congress program see the meeting website.

15e Congrès de l'Encéphale